Nature Communications (Dec 2019)

Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer

  • Sunwang Xu,
  • Ming Zhan,
  • Cen Jiang,
  • Min He,
  • Linhua Yang,
  • Hui Shen,
  • Shuai Huang,
  • Xince Huang,
  • Ruirong Lin,
  • Yongheng Shi,
  • Qiang Liu,
  • Wei Chen,
  • Man Mohan,
  • Jian Wang

DOI
https://doi.org/10.1038/s41467-019-13420-x
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 14

Abstract

Read online

Gemcitabine is used to treat gallbaldder cancer but patient responses are variable. Here, the authors use a genome-wide CRISPR screen and identify the translational elongator protein ELP5 as a protein that is important for mediating gemcitabine-induced apoptosis.